The nurse gives medication to the patient. – PT Roche Indonesia has launched a new formulation of Trusuzumab subcutaneous (SC) administered only 2 to 5 minutes for the treatment of HER2-positive bad cancer.
This formulation is much faster than the one with the old formulation, Trastuzumab Intraven (IV) that takes 30 to 90 minutes.
With a shorter treatment time, it can reduce the queue of patients who will seek treatment. In addition, subcutaneous Trastuzumab provides more comfort to patients and reduces health costs compared to IV.
"Facilitates nursing because it's easier to use," said Musrini, an expert nurse at Dr. Hospital. Trastuzumab substrate is administered by injection into the patient's upper thighs, so it does not extravasate (discharge site) as when using IV. Although faster in the treatment process, but this drug still has side effects to watch.
According to Dr. Nugroho of the Division of Hematology-Medical Oncology Dharmais Cancer Hospital, Trastuzumab Subcutan has side effects on the heart but not permanent. 19659003] "Therefore, we monitor cardiac function, especially if chemotherapy drugs are added in order to double the side effects of the heart, should avoid the use of two drugs in sequence," Nugroho said. ) and sold for 14 million Rp. This price is 35% cheaper than Trastuzumab IV, but this drug is still not included in the drug worn by BPJS.